Sanja Dacic, MD, PhD
Associate Professor of Pathology

Dr. Dacic is a member of the Division of Anatomic Pathology and Director of the FISH and Developmental Laboratory.
Office Location:
Rm. PUH C608
200 Lothrop St.
Pittsburgh, PA 15213
Contact Information:
Office Telephone: 412-647-8694


  • MD - University of Zagreb, Croatia, 1990
  • PhD - University of Zagreb, Croatia, 1998

Clinical Expertise

Dr. Dacic is a thoracic surgical pathologist and Director of the FISH and Developmental Laboratory at the University of Pittsburgh Medical Center. Her diagnostic expertise includes neoplastic and non-neoplastic diseases of the lung, and mediastinum and lung transplantation. FISH and Developmental Laboratory offers a large spectrum of FISH and ISH diagnostic and prognostic tests developed under her direct supervision and guideline.

Research Expertise

Dr. Dacic's primary research interests relate to molecular profiling of lung carcinoma and mesotheliomas and detection of biomarkers that have potential to be used clinically for diagnosis, prognostication and treatment of lung carcinoma and mesotheliomas. These interests resulted in numerous invited lectureships and courses in national and international societies and forums. She is a member of the pathology committee for the International Association for Study of Lung Cancer (IASLC) and a member of International Mesothelioma Panel. Dr. Dacic serves as a Deputy Chief Editor of the Archives of Pathology and Laboratory Medicine. Dr. Dacic is a recipient of Arthur Purdy Stout Prize in 2011 for her research contributions that have had a major impact on diagnostic pathology.

Recent Publications

View Dr. Dacic's publications on PubMed

Chiosea S, Cagle P, Krasinskas A, Zander D, Mitchell K, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 2008; 21 (6):742-7.

Dacic S, Kothmaier H, Land S, Shuai Y , Halbwedl I, Morbini P, Murer B, Comin CE, Galateau-Salle F, Demirag F, Zeren H, Attanoos R, Gibbs A, Cagle PT, HH. Prognostic significance of p16/CDKN2a deletion in pleural malignant mesotheliomas. Virchows Arch 2008;453(6):627-35.

Traynor A, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S, Hoang T, Dubey S, Marcotte S, Siegfried JM. Pilot study of Gefitinib and Fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer 2009;64(1):51-9.

Achcar R, Nikiforova M, Dacic S, Nicholson A, Yousem SA. MAML2 11q21 gene rearrangement in bronchopulmonary mucoepidermoid carcinoma. Hum Pathol 2009;40 (6):854-60.

Monaco S, Nikiforova MN, Cieply K, Teot LA, Khalbuss WE, Dacic S. A comparison of EGFR and KRAS status in primary and matched metastatic pulmonary adenocarcinoma. Hum Pathol 2010 Jan;41(1):94-102. Epub 2009 Sep 8.

Dacic S, Shuai Y, Yousem SA, Ohori NP, Nikiforova MN. Clinico-pathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 2010 Feb;23(2):159-68; 2009 Oct 23. [Epub ahead of print]

Rodig SJ, Mino-Kenudson M, Dacic S, Yeap B Y,. Barletta JA, Stubb H, Law K, Lindeman N, Mark E, Shaw A, Pasi J, Lynch T, Johnson BE, Iafrate AJ, and Chirieac LR. Unique Clinicopathologic features characterize ALK rearranged lung adenocarcinoma in the Western population. Clin Cancer Res 2009; 15(16):5216-23. Epub 2009 Aug 11

Krasinskas AM, Bartlett D, Cieply K, Dacic S. CDKN2A and MTAP deletions in peritoneal mesotheliomas: correlation with loss of p16 protein expression and survival. Mod Pathol 2010 Jan 15. [Epub ahead of print]

Chiosea S, Shuai Y, Cieply K, Nikiforova MN, Dacic S. EGFR FISH positive lung adenocarcinoma: incidence of co-existing KRAS and BRAF mutations. Hum Pathol 2010; 41(8):1053-60.

Dacic S, Kelly L, Shuai Y, Nikiforova MN. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol. 2010; 23(12):1577-82.

Argiris A, Heron DE, Smith R, Kim S, Gibson Michael, Lai S, Branstetter BF, Posluszny D, Wang L, Seethala R, Dacic S, Gooding W, Grandis JR, Johnson JT, Ferris RL. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer J Clin Oncol 2010; 20;28(36):5294-300.

Tarhini A, Kotsakis, A, Gooding W, Shuai Y, Petro D, Friedland D, Belani CP, Dacic S, Argiris A. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 2010;16(23):5900-7.

Cagle PT, Allen TC, Dacic S, Beasley MB, Borczuk AC, Chirieac LR, Laucirica R, Ro JY, Kerr KM. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med. 2011;135(1):110-6

García JJ, Hunt JL, Weinreb I, McHugh JB, Barnes EL, Cieply K, Dacic S, Seethala RR. Fluorescent in situ hybridization for detection of MAML2 rearrangements in oncocytic mucoepidermoid carcinomas: utility as a diagnostic test Hum Pathol 2011 Jul 19

Monaco SE, Krasinskas AM, Kamat, Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemistry in mesothelial proliferations diagnosed by surgical pathology and cytology. Am J Clin Pathol 2011;135(4):619-27

Stabile LP, Dacic S, Land SR, Lenzner D, Dhir R, Aquafondata M, Landreneau RJ, Grandis JR, Siegfried JM. Combined analysis of estrogen receptor-beta and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res 2011; 1;17(1):154-64.

Tochigi N, Dacic S, Ohori NP. Bronchoscopic and transthoracic cytology and biopsy for pulmonary non-small cell carcinomas:performance characteristics by procedure and tumor type. Diagn Cytopathol. 2011 Feb 13. doi: 10.1002/dc.21588. [Epub ahead of print]

Tochigi N, Dacic S, Nikiforova M, Cieply KM, Yousem SA. Adenosquamous carcinoma of lung: a microdissection study of KRAS and EGFR mutational and amplification status in a Western patient population. Am J Clin Pathol 2011; 135(5):983-9.

Ocque R, Tochigi N, Ohori PN, Dacic S. Utility of immunohistochemistry and histochemistry in the classification of lung adenocarcinoma and squamous cell carcinoma in cytology specimens. Am J Clin Pathol 2011;135(5):783-9.

Xue J, Gochuico B, Alawad AS, Feghali-Bostwick CA, Noth I, Nathn S D, Rosen GD, Rosas IO, Dacic S, Ocak I, Fuhrman CR, Cuenco KT, Smith MA, Jacobs SS, Zeevi, A, Morel PA, Pilewski JM, Valentine VG, Gibson KF, Kaminski N, Sciurba FC, Zhang Y, Duncan SR. The HLA class II allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. PLoS One 2011 Feb 23; 6(2):e14715

Noeln BM, Langmead CJ, Choi S, Lomakin A, Marrangoni A, Bigbee WL, Wiessfeld JL, Wilson DO, Dacic S, Siegfried JM, Lokshin AE. Serum biomarker profiles as screening tools in lung cancer. Cancer Biomark. 2011 Jan 1;10(1):3-12.

Chiosea S, Sherer C, Jelic T, Dacic S. KRAS Mutant allele specific imbalance in lung adenocarcinoma. Mod Pathol 2011 Dec;24(12):1571-7. doi: 10.1038/modpathol.2011.109. Epub 2011 Jul 8.

Tessema M, Yingling CM, Thomas CL, Klinge DM, Bernauer A, Liu Y, Dacic S, Siegfried JM, Dahlberg S, Schiller J, Belinsky SA. SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via Induction of ISG15. Oncogene 2011 Dec 12. doi: 10.1038/onc.2011.577